BRIEF-Ligand Partner Verona Pharma Announces FDA Approval Of Ohtuvayre For Maintenance Treatment Of COPD

Reuters06-27 20:42

June 27 (Reuters) - Ligand Pharmaceuticals Inc :

* LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS

* LIGAND PHARMACEUTICALS INC: ENTITLED TO RECEIVE A LOW SINGLE-DIGIT ROYALTY ON WORLDWIDE NET SALES OF OHTUVAYRE

* LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446341725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-27 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446341725","market":"us","top_or_hot":-1,"title":"BRIEF-Ligand Partner Verona Pharma Announces FDA Approval Of Ohtuvayre For Maintenance Treatment Of COPD","media":"Reuters","content":"<html><body><p>June 27 (Reuters) - Ligand Pharmaceuticals Inc   :</p><p>   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS</p><p>   * LIGAND PHARMACEUTICALS INC: ENTITLED TO RECEIVE A LOW SINGLE-DIGIT ROYALTY ON WORLDWIDE NET SALES OF OHTUVAYRE</p><p>   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ligand Partner Verona Pharma Announces FDA Approval Of Ohtuvayre For Maintenance Treatment Of COPD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ligand Partner Verona Pharma Announces FDA Approval Of Ohtuvayre For Maintenance Treatment Of COPD\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-27 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 27 (Reuters) - Ligand Pharmaceuticals Inc   :   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2446341725","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446341725","pubTimestamp":1719492124,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"June 27  - Ligand Pharmaceuticals Inc   :   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE , FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS   * LIGAND PHARMACEUTICALS INC: ENTITLED TO RECEIVE A LOW SINGLE-DIGIT ROYALTY ON WORLDWIDE NET SALES OF OHTUVAYRE   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE , FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"BRIEF-Ligand合作伙伴Verona Pharma宣布FDA批准Ohtuvayre用于COPD维持治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":0.9},"content_text":"June 27 (Reuters) - Ligand Pharmaceuticals Inc   :   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS   * LIGAND PHARMACEUTICALS INC: ENTITLED TO RECEIVE A LOW SINGLE-DIGIT ROYALTY ON WORLDWIDE NET SALES OF OHTUVAYRE   * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446341725"}